Amanote Research

Amanote Research

    RegisterSign In

Maintenance PARP Inhibitor Therapy: Is Maintaining Quality of Life Enough?

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(18)30623-5
Full Text
Open PDF
Abstract

Available in full text

Categories
Oncology
Date

October 1, 2018

Authors
Sara BouberhanMeghan SheaStephen A Cannistra
Publisher

Elsevier BV


Related search

F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Molecular Cell
Cell BiologyMolecular Biology
2019English

Is Life Precious Enough for All?

BJPsych. International
2016English

Quality of Life Reporting in Multiple Sclerosis Clinical Trials: Enough Quality?

Multiple Sclerosis
Neurology
2012English

MS21.05 Quality of Life - Are We Paying Enough Attention?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Enough Is Enough.

BMJ
1982English

When Standard Cognitive-Behavioural Therapy Is Not Enough

Psychiatric Bulletin
2007English

The MSF: Enough Is Enough

Desalination and Water Treatment
Ocean EngineeringTechnologyWater SciencePollution
2010English

Not Enough Points Is Enough

Lecture Notes in Computer Science
Computer ScienceTheoretical Computer Science
English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy